Загрузка...
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating...
Сохранить в:
| Опубликовано в: : | Cells |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8157002/ https://ncbi.nlm.nih.gov/pubmed/34067729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10051225 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|